Have I been tested for all actionable mutations including EGFR, ALK, ROS1, and KRAS G12C

TL;DR: Since you're on Tagrisso (an EGFR-targeted drug), you've definitely been tested for EGFR mutations — but you should confirm whether you were also tested for ALK, ROS1, and KRAS G12C, especially since brain metastases can sometimes have different mutations than the original tumor.

---

KEY POINTS:

• You have EGFR-mutant lung cancer — Tagrisso targets EGFR mutations, so that testing was done and came back positive
• Brain metastases may need separate testing — the mutations in brain lesions can sometimes differ from the original lung tumor
• ALK, ROS1, and KRAS G12C testing is standard — according to NCCN Guidelines, these should have been tested on your initial biopsy
• If you haven't seen a written report listing all mutations tested, ask for it — you need documentation of what was checked and what was found
• Liquid biopsy (blood test) can catch new mutations — as your cancer evolves, new mutations may emerge that weren't present at diagnosis

---

NEXT STEP:

Ask your oncologist: "Can you send me a copy of my complete molecular testing report that lists ALL the genes that were tested (EGFR, ALK, ROS1, KRAS, BRAF, etc.) and which ones were positive or negative?"

---

FULL ANSWER

Your Situation: EGFR-Mutant Lung Cancer with Brain Metastases

Based on your medical history, you have stage 4 (metastatic) adenocarcinoma with EGFR mutations — we know this because you responded to Tagrisso (osimertinib), which is an EGFR-targeted therapy. This tells us your initial testing found an EGFR mutation.

However, your question about whether you've been tested for all actionable mutations is important, especially given your brain metastases and multiple rounds of treatment.

---

What the NCCN Guidelines Say About Your Testing

According to NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung Cancer (2024), comprehensive biomarker testing should include:

Standard driver mutations tested:

• ✅ EGFR — you have this (that's why Tagrisso works)
• ALK rearrangement — should have been tested
• ROS1 rearrangement — should have been tested
• KRAS G12C — should have been tested
• BRAF V600E — should have been tested
• NTRK gene fusion — should have been tested
• MET exon 14 skipping — should have been tested
• RET rearrangement — should have been tested
• ERBB2 (HER2) mutation — should have been tested

Immune markers:

• PD-L1 expression — important for immunotherapy decisions

---

Why This Matters for Your Treatment Plan

According to NCCN Guidelines, if you have multiple actionable mutations, your treatment options expand. For example:

• If you also had ALK or ROS1, you might have additional targeted therapy options
• If you have KRAS G12C, newer drugs like sotorasib or adagrasib are now FDA-approved and could be relevant
• Your PD-L1 status determines whether immunotherapy (like the alimta maintenance you're receiving) is appropriate

---

Important: Brain Metastases May Have Different Mutations

This is a critical point: The mutations in your brain lesions may be different from the mutations in your original lung tumor.

According to research on metastatic cancer, as tumors spread and evolve, they can acquire new mutations or lose old ones. Since you've had:

1. Initial Tagrisso treatment
2. Carboplatin + alimta induction
3. Alimta maintenance (3 cycles so far)
4. Gamma Knife radiation twice

...your cancer has had time to evolve. New mutations may have emerged that weren't present at your initial diagnosis.

---

What You Should Do Now

Step 1: Get your original molecular testing report

• Ask your oncology team: "Can you send me a copy of my complete tumor sequencing report from my initial biopsy?"
• This should list every gene tested and whether each one was positive or negative
• Look for a document that says "NGS panel," "comprehensive genomic profiling," "tumor sequencing," or "molecular testing"

Step 2: Confirm what was tested

• The report should show a list like: EGFR ✓, ALK ✗, ROS1 ✗, KRAS ✗, etc.
• If it only shows EGFR and a few others, you may not have had comprehensive testing

Step 3: Ask about repeat testing

• Given your brain metastases and treatment progression, ask: "Should I have repeat molecular testing now to see if new mutations have emerged?"
• This is especially relevant if your cancer is progressing or if you're considering changing treatment

Step 4: Consider liquid biopsy

• According to CancerPatientLab webinars on liquid biopsies, blood-based tests can detect circulating tumor DNA (ctDNA) and may catch new mutations as your cancer evolves
• Ask your doctor: "Would a liquid biopsy be helpful to monitor for new mutations?"

---

Questions to Ask Your Oncologist

1. "What was my original molecular testing panel, and which genes were tested?"
2. "Which mutations came back positive, and which came back negative?"
3. "Given my brain metastases, should I have repeat molecular testing to see if new mutations have emerged?"
4. "Do I have any other actionable mutations besides EGFR that might open up additional treatment options?"
5. "Would a liquid biopsy be useful for monitoring my cancer as it evolves?"

---

Why Upload Your Reports Here?

If you can upload your molecular testing report, pathology report, or any sequencing results, I can:

• Tell you exactly which mutations were tested
• Explain what each result means
• Identify any actionable mutations you might not be aware of
• Help you prepare more specific questions for your oncologist

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.